NAD+ and Aging: Mechanism vs Marketing
The biology is genuinely interesting. The supplement claims often outrun what's been shown in people.
NAD+ sits at an awkward intersection of real science and aggressive marketing. The underlying biology is legitimately interesting — NAD+ is a coenzyme central to energy metabolism, and its levels appear to decline with age. That observation has spawned a large supplement market built around “restoring” NAD+. The distance between the genuine mechanistic interest and the confident promises on the label is the thing worth examining carefully.
The biology that makes it interesting
NAD+ (nicotinamide adenine dinucleotide) is involved in hundreds of cellular reactions, including those that generate energy and those that govern DNA repair and the activity of enzymes called sirtuins, which are tied to several aging-related processes. There’s reasonable evidence that NAD+ availability declines with age across tissues, and that lower NAD+ could plausibly impair these maintenance functions.
That’s a coherent and testable hypothesis: if declining NAD+ contributes to aspects of aging, raising it might help. Much of the supplement market focuses on precursors — molecules like NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) — because directly supplementing NAD+ itself is impractical.
Precursor supplements can raise circulating NAD+ markers in people — that part is reasonably shown. Whether raising those markers translates into slower aging or better health outcomes is the question that hasn’t been answered.
Where marketing gets ahead of the data
This is the crux. Human trials of NR and NMN have generally shown they can increase NAD+ levels and are reasonably well tolerated in the short term. What they have largely not shown is robust, consistent improvement in the meaningful outcomes the marketing implies — energy, healthspan, age reversal, athletic performance.
A few honest points:
- Biomarker ≠ benefit. Raising a measurable level is not the same as improving how you age. The trials linking the two in humans are small and inconsistent.
- Animal data is more promising than human data, and the leap between them is exactly where many supplement claims overreach.
- Open safety questions remain for long-term use, and the regulatory oversight of these products is limited.
A reasonable way to hold it
The science justifies continued research, not the breathless claims. It’s a domain where “interesting hypothesis under investigation” is the accurate frame.
The takeaway
NAD+ biology is a real and active area of aging research, and precursor supplements can genuinely raise NAD+ markers. But raising a marker is not the same as slowing aging, and the human evidence for the outcomes people actually care about is thin and mixed. The mechanism deserves attention; the marketing deserves skepticism. If you see confident promises of energy, rejuvenation, or longevity from an NAD+ product, the data doesn’t yet earn that confidence.
This is sample content created during site scaffolding. Replace with reviewed, fully-cited editorial before launch.